BFC
MRNA icon

Blue Fin Capital’s Moderna MRNA Stock Holding History

Blue Fin Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,819
Closed -$335K – 145
2024
Q2 		$335K Buy
2,819
+23
+0.8% +$2.91K 0.07% 117
2024
Q1 		$298K Buy
2,796
+568
+25% +$57.3K 0.07% 120
2023
Q4 		$222K Buy
+2,228
New +$187K 0.06% 134
2023
Q3 		– Sell
-1,849
Closed -$225K – 130
2023
Q2 		$225K Buy
1,849
+40
+2% +$5.34K 0.06% 128
2023
Q1 		$243K Buy
1,809
+42
+2% +$6.93K 0.08% 122
2022
Q4 		$317K Sell
1,767
-99
-5% -$16.2K 0.12% 106
2022
Q3 		$220K Buy
1,866
+11
+0.6% +$1.67K 0.08% 119
2022
Q2 		$264K Sell
1,855
-105
-5% -$15K 0.09% 114
2022
Q1 		$337K Buy
1,960
+514
+36% +$86.5K 0.1% 103
2021
Q4 		$367K Buy
1,446
+715
+98% +$209K 0.1% 101
2021
Q3 		$281K Buy
+731
New +$270K 0.09% 110

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Blue Fin Capital's MRNA Position: Q3 2024 in Review

Blue Fin Capital sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,819 shares — an estimated $335K sold.

Blue Fin Capital first reported a position in MRNA in Q3 2021 and held it in 11 quarters. The position peaked at $367K in Q4 2021. 789 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Blue Fin Capital reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Blue Fin Capital sold 2,819 Moderna shares in Q3 2024, an estimated $335K.
  • Blue Fin Capital first reported a position in Moderna in Q3 2021 and held it in 11 quarters.
  • Blue Fin Capital's Moderna position peaked at $367K in Q4 2021.
  • 789 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Blue Fin Capital's 13F filing for Q3 2024, filed 5 Nov 2024.